H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $10 from $7 and keeps a Buy rating ...

Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with ...

Q4 2024 Earnings Call Transcript March 18, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica ...

DiaMedica Therapeutics Inc.’s DMAC share price has dipped by 13.02%, which has investors questioning if this is right time to buy.

After hours: March 18 at 6:53:00 PM EDT Loading Chart for BCRX ...

At close: March 17 at 4:00:00 PM EDT Loading Chart for RZLT ...

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and ...

After hours: March 14 at 7:54:05 p.m. EDT Loading Chart for KALV ...